Shares of MGC Pharmaceuticals Limited (LON:MXC – Get Rating) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as GBX 0.85 ($0.01) and last traded at GBX 0.89 ($0.01), with a volume of 1437603 shares. The stock had previously closed at GBX 0.93 ($0.01).
MGC Pharmaceuticals Stock Performance
The company has a market capitalization of £25.48 million and a price-to-earnings ratio of -2.24. The company has a current ratio of 1.05, a quick ratio of 0.68 and a debt-to-equity ratio of 41.72. The stock has a 50-day simple moving average of GBX 1.03 and a 200-day simple moving average of GBX 1.11.
About MGC Pharmaceuticals
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia.
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for MGC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MGC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.